Pulmonary alveolar microlithiasis

Last updated
Pulmonary alveolar microlithiasis
Autosomal recessive - en.svg
Pulmonary alveolar microlithiasis is inherited in an autosomal recessive manner
Specialty Pulmonology   OOjs UI icon edit-ltr-progressive.svg

Pulmonary alveolar microlithiasis (PAM) is a rare, inherited disorder of lung phosphate balance that is associated with small stone formation in the airspaces of the lung. Mutations in the gene SLC34A2 [1] [2] result in loss of a key sodium, phosphate co-transporter (called Npt2b), known to be expressed in distal alveolar type II cells, as well as in the mammary gland, and to a lesser extent in intestine, kidney, skin, prostate and testes. As the disease progresses, the lung fields become progressively more dense (white) on the chest xray, and low oxygen level, lung inflammation and fibrosis, elevated pressures in the lung blood vessels, and respiratory failure ensue, usually in middle age. The clinical course of PAM can be highly variable, with some patients remaining asymptomatic for decades, and others progressing more rapidly. There is no effective treatment, and the mechanisms of stone formation, inflammation and scarring are not known.

Contents

Signs and symptoms

Patients typically have no symptoms until the third or fourth decade of life, although complications in childhood have been recorded [3] [4] In most cases, the disease is discovered incidentally on routine chest Xray. The most common symptoms include the following: [5] [6] [7] [8] [9]

Genetics

PAM is hereditary and another involved family member can be identified in 36% to 61% of cases. [6] Impaired activity of the SLC34A2 gene is responsible for PAM. [1] [2] [7] [10] [11] [12] [ excessive citations ] At present, 27 mutations are known to be related to the development of the pulmonary alveolar microlithiasis phenotype and manifestation of the disorder, and of these mutations most genotypes reveal a homozygous mutation of the SLC34A2 gene. [13] The SLC34A2 gene encodes a membrane protein that is expressed primarily in the apical portions of alveolar type II cells [14] and is the most abundant phosphate carrier in the lungs. [7] Identified on chromosome 4p15, the SLC34A gene encodes Npt2b, the sodium phosphate co-transporter, and 12 of the 13 exons located within the gene encode this co-transporter. [13]

Pathogenesis

Histopathology of an alveolar microlith. Histopathology of pulmonary alveolar microlithiasis.jpg
Histopathology of an alveolar microlith.

Type II alveolar cells have many important functions in the lung, including the production of pulmonary surfactant, maintenance of fluid balance and composition in the airspace. Phospholipids that make up pulmonary surfactant are broken down by macrophages, releasing phosphate into the alveolar lining fluid. The loss of the Npt2b phosphate transported eliminates the ability of alveolar type II cells to pump phosphorus ions from the alveolar space back into the bloodstream, and leads to microlith formation. [7] [15]

Epithelial deletion of Npt2b in mice results in an authentic mimic of the human condition, including accumulation of calcium phosphate microliths in the lung tissue and progressive diffuse radiographic opacities. The mouse model provides a useful platform for preclinical studies, including therapeutic trials of EDTA lavage and low phosphate diet/phosphate binders. [16]

Pathology

PAM may be confined to certain areas or show diffuse distribution through the lungs. [8] Lung biopsy and autopsy specimens demonstrate characteristic intra-alveolar lamellar microliths. [8] [17] Calcium deposits in the alveoli begin in the lower lobes and spread over a period of years throughout the lungs. [5]

Diagnosis

PAM is usually diagnosed on the basis of a typical radiological pattern, namely a very fine, sand-like micronodulation of calcific density diffusely involving both lungs, with basal predominance. Many authors argue that this pattern precludes the need for a lung biopsy in most cases. [5] [18] [19] After PAM is diagnosed in a given patient, family members should be screened by chest radiography, and parents should be counseled that future children are also at risk of developing the disease. [20]

Radiology

Chest radiographs of patients with PAM usually reveal bilateral diffuse micronodular calcifications, producing a "sandstorm” appearance that first involves the inferior portions and then the middle and upper portions of the lungs. [5]

High-resolution computed tomography

The most common findings on HRCT are diffuse hyperdense ground-glass attenuation and subpleural linear calcifications, often most predominant in the inferior and posterior portions of the lungs. [18] [21] [22] [23] [24] [25] Additionally, the medial aspects of the lungs appear to be more heavily involved than the lateral aspects. [23] Ground-glass opacities, probably due to small calculi in the air space, are the most common finding in children and in patients with early-stage PAM. [22]

Magnetic resonance imaging

On magnetic resonance imaging (MRI), the calcific lesions usually show hypointensity or a signal void on T1- and T2-weighted images.[ citation needed ]

Pulmonary function studies

Pulmonary function tests, arterial blood gases, ventilation perfusion relationships, and O2 diffusing capacity are normal in the initial stages of PAM. As the disease progresses, pulmonary function tests reveal typical features of a restrictive defect with reduced forced vital capacity (FVC) and elevated forced expiratory volume in FEV1/FVC.[ citation needed ]

Treatment

To date, no treatment has been proven to reverse or prevent the progression of PAM effectively. Lung transplantation is an option for the end-stage disease but is typically only recommended as a last resort when the quality of life is significantly impaired. [26]

Although no effective treatment exists, there are several common supportive care approaches that can alleviate symptoms resulting from PAM. Domiciliary oxygen should be prescribed to the patient for hypoxemia to prevent manifest desaturation. [27] [28]

Etidronate is a bisphosphonate and can reduce the formation of calcium hydroxyapatite crystals. It has led to clinical and radiological improvements in few cases. [29]

Smoking should be prohibited for patients to avoid exacerbating disease progression. [30]

Epidemiology

Since the disease was first described in 1918, over 500 case reports have appeared in the literature. [31] PAM is associated with consanguinity. The incidence is higher in Turkey, Japan, India and Italy. [32] The disease affects both men and women equally, and it has been associated with intermarriage within families. [33] The mean age at diagnosis is 35 years based on the cases reported in the literature.[ citation needed ]

Society

PAM is one of the rare lung diseases currently being studied by the Rare Lung Diseases Consortium. Pulmonary Alveolar Microlithiasis patients, families, and caregivers are encouraged to join the NIH Rare Lung Diseases Consortium Contact Registry. This is a privacy protected site that provides up-to-date information for individuals interested in the latest scientific news, trials, and treatments related to rare lung diseases.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Berylliosis</span> Medical condition

Berylliosis, or chronic beryllium disease (CBD), is a chronic allergic-type lung response and chronic lung disease caused by exposure to beryllium and its compounds, a form of beryllium poisoning. It is distinct from acute beryllium poisoning, which became rare following occupational exposure limits established around 1950. Berylliosis is an occupational lung disease.

<span class="mw-page-title-main">Asbestosis</span> Pneumoconiosis caused by inhalation and retention of asbestos fibers

Asbestosis is long-term inflammation and scarring of the lungs due to asbestos fibers. Symptoms may include shortness of breath, cough, wheezing, and chest tightness. Complications may include lung cancer, mesothelioma, and pulmonary heart disease.

<span class="mw-page-title-main">Pulmonary alveolar proteinosis</span> Medical condition

Pulmonary alveolar proteinosis (PAP) is a rare lung disorder characterized by an abnormal accumulation of surfactant-derived lipoprotein compounds within the alveoli of the lung. The accumulated substances interfere with the normal gas exchange and expansion of the lungs, ultimately leading to difficulty breathing and a predisposition to developing lung infections. The causes of PAP may be grouped into primary, secondary, and congenital causes, although the most common cause is a primary autoimmune condition in an individual.

<span class="mw-page-title-main">Primary familial brain calcification</span> Indiana genetic disorder involving calcification of the basal ganglia

Primary familial brain calcification (PFBC), also known as familial idiopathic basal ganglia calcification (FIBGC) and Fahr's disease, is a rare, genetically dominant or recessive, inherited neurological disorder characterized by abnormal deposits of calcium in areas of the brain that control movement. Through the use of CT scans, calcifications are seen primarily in the basal ganglia and in other areas such as the cerebral cortex.

<span class="mw-page-title-main">Interstitial lung disease</span> Group of diseases

Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium and space around the alveoli of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases.

<span class="mw-page-title-main">Chest radiograph</span> Projection X-ray of the chest

A chest radiograph, chest X-ray (CXR), or chest film is a projection radiograph of the chest used to diagnose conditions affecting the chest, its contents, and nearby structures. Chest radiographs are the most common film taken in medicine.

<span class="mw-page-title-main">Lymphangioleiomyomatosis</span> Medical condition

Lymphangioleiomyomatosis (LAM) is a rare, progressive and systemic disease that typically results in cystic lung destruction. It predominantly affects women, especially during childbearing years. The term sporadic LAM is used for patients with LAM not associated with tuberous sclerosis complex (TSC), while TSC-LAM refers to LAM that is associated with TSC.

<span class="mw-page-title-main">Cryptogenic organizing pneumonia</span> Medical condition

Cryptogenic organizing pneumonia (COP), formerly known as bronchiolitis obliterans organizing pneumonia (BOOP), is an inflammation of the bronchioles (bronchiolitis) and surrounding tissue in the lungs. It is a form of idiopathic interstitial pneumonia.

<span class="mw-page-title-main">Lipid pneumonia</span> Lung inflammation caused by lipids in the bronchial tree

Lipoid pneumonia is a specific form of lung inflammation (pneumonia) that develops when lipids enter the bronchial tree. The disorder is sometimes called cholesterol pneumonia in cases where that lipid is a factor.

<span class="mw-page-title-main">Nephrocalcinosis</span> Medical condition caused by the deposition of calcium salts in the kidneys

Nephrocalcinosis, once known as Albright's calcinosis after Fuller Albright, is a term originally used to describe the deposition of poorly soluble calcium salts in the renal parenchyma due to hyperparathyroidism. The term nephrocalcinosis is used to describe the deposition of both calcium oxalate and calcium phosphate. It may cause acute kidney injury. It is now more commonly used to describe diffuse, fine, renal parenchymal calcification in radiology. It is caused by multiple different conditions and is determined by progressive kidney dysfunction. These outlines eventually come together to form a dense mass. During its early stages, nephrocalcinosis is visible on x-ray, and appears as a fine granular mottling over the renal outlines. It is most commonly seen as an incidental finding with medullary sponge kidney on an abdominal x-ray. It may be severe enough to cause renal tubular acidosis or even end stage kidney disease, due to disruption of the kidney tissue by the deposited calcium salts.

<span class="mw-page-title-main">Adenocarcinoma in situ of the lung</span> Medical condition

Adenocarcinoma in situ (AIS) of the lung —previously included in the category of "bronchioloalveolar carcinoma" (BAC)—is a subtype of lung adenocarcinoma. It tends to arise in the distal bronchioles or alveoli and is defined by a non-invasive growth pattern. This small solitary tumor exhibits pure alveolar distribution and lacks any invasion of the surrounding normal lung. If completely removed by surgery, the prognosis is excellent with up to 100% 5-year survival.

<span class="mw-page-title-main">Sodium-dependent phosphate transport protein 2B</span> Protein-coding gene in the species Homo sapiens

Sodium-dependent phosphate transport protein 2B (NaPi2b) is a protein that in humans is encoded by the SLC34A2 gene.

<span class="mw-page-title-main">Keutel syndrome</span> Medical condition

Keutel syndrome (KS) is a rare autosomal recessive genetic disorder characterized by abnormal diffuse cartilage calcification, hypoplasia of the mid-face, peripheral pulmonary stenosis, hearing loss, short distal phalanges (tips) of the fingers and mild mental retardation. Individuals with KS often present with peripheral pulmonary stenosis, brachytelephalangism, sloping forehead, midface hypoplasia, and receding chin. It is associated with abnormalities in the gene coding for matrix gla protein, MGP. Being an autosomal recessive disorder, it may be inherited from two unaffected, abnormal MGP-carrying parents. Thus, people who inherit two affected MGP alleles will likely inherit KS.

<span class="mw-page-title-main">Lung nodule</span> Medical condition

A lung nodule or pulmonary nodule is a relatively small focal density in the lung. A solitary pulmonary nodule (SPN) or coin lesion, is a mass in the lung smaller than three centimeters in diameter. A pulmonary micronodule has a diameter of less than three millimetres. There may also be multiple nodules.

Alveolar capillary dysplasia (ACD) is a rare, congenital diffuse lung disease characterized by abnormal blood vessels in the lungs that cause highly elevated pulmonary blood pressure and an inability to effectively oxygenate and remove carbon dioxide from the blood. ACD typically presents in newborn babies within hours of birth as rapid and labored breathing, blue-colored lips or skin, quickly leading to respiratory failure and death. Atypical forms of ACD have been reported with initially milder symptoms and survival of many months before the onset of respiratory failure or lung transplantation.

Generalized arterial calcification of infancy (GACI) is an extremely rare genetic disorder. It is caused by mutations in the ENPP1 gene in 75% of the subjects or in mutations in the ABCC6 genes in 10% of patients. However, sometimes individuals affected with GACI do not have mutations in the ENPP1 or ABCC6 gene and in those cases the cause of the disorder is unknown.

Surfactant metabolism dysfunction is a condition where pulmonary surfactant is insufficient for adequate respiration. Surface tension at the liquid-air interphase in the alveoli makes the air sacs prone to collapsing post expiration. This is due to the fact that water molecules in the liquid-air surface of alveoli are more attracted to one another than they are to molecules in the air. For sphere-like structures like alveoli, water molecules line the inner walls of the air sacs and stick tightly together through hydrogen bonds. These intermolecular forces put great restraint on the inner walls of the air sac, tighten the surface all together, and unyielding to stretch for inhalation. Thus, without something to alleviate this surface tension, alveoli can collapse and cannot be filled up again. Surfactant is essential mixture that is released into the air-facing surface of inner walls of air sacs to lessen the strength of surface tension. This mixture inserts itself among water molecules and breaks up hydrogen bonds that hold the tension. Multiple lung diseases, like ISD or RDS, in newborns and late-onsets cases have been linked to dysfunction of surfactant metabolism.

<span class="mw-page-title-main">Ground-glass opacity</span> Radiologic sign on radiographs and computed tomography scans

Ground-glass opacity (GGO) is a finding seen on chest x-ray (radiograph) or computed tomography (CT) imaging of the lungs. It is typically defined as an area of hazy opacification (x-ray) or increased attenuation (CT) due to air displacement by fluid, airway collapse, fibrosis, or a neoplastic process. When a substance other than air fills an area of the lung it increases that area's density. On both x-ray and CT, this appears more grey or hazy as opposed to the normally dark-appearing lungs. Although it can sometimes be seen in normal lungs, common pathologic causes include infections, interstitial lung disease, and pulmonary edema.

<span class="mw-page-title-main">Asbestos-related diseases</span> Medical condition

Asbestos-related diseases are disorders of the lung and pleura caused by the inhalation of asbestos fibres. Asbestos-related diseases include non-malignant disorders such as asbestosis, diffuse pleural thickening, pleural plaques, pleural effusion, rounded atelectasis and malignancies such as lung cancer and malignant mesothelioma.

Vaping-associated pulmonary injury (VAPI), also known as vaping-associated lung injury (VALI) or e-cigarette, or vaping, product use associated lung injury (E/VALI), is an umbrella term, used to describe lung diseases associated with the use of vaping products that can be severe and life-threatening. Symptoms can initially mimic common pulmonary diagnoses, such as pneumonia, but sufferers typically do not respond to antibiotic therapy. Differential diagnoses have overlapping features with VAPI, including COVID-19. According to a systematic review article, "Initial case reports of vaping-related lung injury date back to 2012, but the ongoing outbreak of EVALI began in the summer of 2019." According to an article in the Radiological Society of North America news published in March 2022, EVALI cases continue to be diagnosed. “EVALI has by no means disappeared,” Dr. Kligerman said. “We continue to see numerous cases, even during the pandemic, many of which are initially misdiagnosed as COVID-19.”

References

  1. 1 2 Huqun; Izumi, S; Miyazawa, H; Ishii, K; Uchiyama, B; Ishida, T; Tanaka, S; Tazawa, R; Fukuyama, S; Tanaka, T; Nagai, Y; Yokote, A; Takahashi, H; Fukushima, T; Kobayashi, K; Chiba, H; Nagata, M; Sakamoto, S; Nakata, K; Takebayashi, Y; Shimizu, Y; Kaneko, K; Shimizu, M; Kanazawa, M; Abe, S; Inoue, Y; Takenoshita, S; Yoshimura, K; Kudo, K; Tachibana, T; Nukiwa, T; Hagiwara, K (2007). "Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis". Am J Respir Crit Care Med. 175 (3): 263–268. doi:10.1164/rccm.200609-1274oc. PMID   17095743.
  2. 1 2 Corut, A; Senyigit, A; Ugur, SA; Altin, S; Ozcelik, U; Calisir, H; Yildirim, Z; Gocmen, A; Tolun, A (2006). "Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis". Am J Hum Genet. 79 (4): 650–656. doi:10.1086/508263. PMC   1592565 . PMID   16960801.
  3. ↑ Al-Maghrabi, Haneen; Mokhtar, Ghadeer; Al-Maghrabi, Jaudah; Meliti, Abdelrazak (2020). "Pulmonary alveolar microlithiasis: A report of two unique cases". Respiratory Medicine Case Reports. 29: 100980. doi:10.1016/j.rmcr.2019.100980. ISSN   2213-0071. PMC   6928350 . PMID   31890557.
  4. ↑ Zhang, Meiyu; Gao, Man; Liu, Yuhuan; Wang, Kun; Zhou, Siyan; Jing, Haoran; Yin, Guo; Meng, Fanzheng (August 2023). "Two novel gene mutations identified in a child with pulmonary alveolar microlithiasis complicated with bronchitis obliterans: A case report and literature review". Clinical Case Reports. 11 (8): e7726. doi:10.1002/ccr3.7726. ISSN   2050-0904. PMID   37575464.
  5. 1 2 3 4 Mariotta, S; Ricci, A; Papale, M; DeClementi, F; Sposato, B; Guidi, L; et al. (2004). "Pulmonary alveolar microlithiasis: report on 576 cases published in the literature". Sarcoidosis Vasc Diffuse Lung Dis. 21 (3): 173–181. PMID   15554073.
  6. 1 2 Castellana, G; Lamorgese, V (2003). "Pulmonary alveolar microlithiasis. World cases and review of the literature". Respiration. 70 (5): 549–555. doi:10.1159/000074218. PMID   14665786. S2CID   24718986.
  7. 1 2 3 4 Tachibana, T; Hagiwara, K; Johkoh, T (2009). "Pulmonary alveolar microlithiasis: review and management". Curr Opin Pulm Med. 15 (5): 486–490. doi:10.1097/mcp.0b013e32832d03bb. PMID   19617834. S2CID   39146922.
  8. 1 2 3 Lauta, VM (2003). "Pulmonary alveolar microlithiasis: an overview of clinical and pathological features together with possible therapies". Respir Med. 97 (10): 1081–1085. doi: 10.1016/s0954-6111(03)00140-9 . PMID   14561014.
  9. ↑ Korn, MA; Schurawitzki, H; Klepetko, W; Burghuber, OC (1992). "Pulmonary alveolar microlithiasis: findings on high-resolution CT". AJR Am J Roentgenol. 158 (5): 981–982. doi:10.2214/ajr.158.5.1566701. PMID   1566701.
  10. ↑ Senyiğit, A; Yaramiş, A; Gürkan, F; Kirbaş, G; Büyükbayram, H; Nazaroğlu, H; Alp, MN; Topçu, F (2001). "Pulmonary alveolar microlithiasis: a rare familial inheritance with report of six cases in a family. Contribution of six new cases to the number of case reports in Turkey". Respiration. 68 (2): 204–209. doi:10.1159/000050494. PMID   11287838. S2CID   72278974.
  11. ↑ Huqun; Izumi, S; Miyazawa, H; Ishii, K; Uchiyama, B; Ishida, T; et al. (2006). "The autozygous segments predicted by a genome-wide SNP typing revealed mutations in the type IIb sodium phosphate cotransporter (SLC34A2) causing pulmonary alveolar microlithiasis". Proc Am Thorac Soc. 3: A102.
  12. ↑ Hagiwara, K; Johkoh, T; Tachibana, T (2009). Pulmonary alveolar microlithiasis. New Jersey: Humana Press.
  13. 1 2 Kosciuk, Patrick; Meyer, Cristopher; Wikenheiser-Brokamp, Kathryn A.; McCormack, Francis X. (2020-12-31). "Pulmonary alveolar microlithiasis". European Respiratory Review. 29 (158): 200024. doi: 10.1183/16000617.0024-2020 . ISSN   0905-9180. PMC   9488654 . PMID   33246992.
  14. ↑ Traebert, M; Hattenhauer, O; Murer, H; Kaissling, B; Biber, J (1999). "Expression of type II Na-P(i) cotransporter in alveolar type II cells". Am J Physiol. 277 (5 Pt 1): 868–873. doi:10.1152/ajplung.1999.277.5.L868. PMID   10564169. S2CID   34126804.
  15. ↑ Poelma, DL; Ju, MR; Bakker, SC; Zimmermann, LJ; Lachmann, BF; van Iwaarden, JF (2004). "A common pathway for the uptake of surfactant lipids by alveolar cells". Am J Respir Cell Mol Biol. 30 (5): 751–758. CiteSeerX   10.1.1.323.3865 . doi:10.1165/rcmb.2003-0127oc. PMID   14644915.
  16. ↑ Saito, A; Nikolaidis, NM; Amlal, H; Uehara, Y; Gardner, JC; LaSance, K; Pitstick, LB; Bridges, JP; Wikenheiser-Brokamp, KA; McGraw, DW; Woods, JC; Sabbagh, Y; Schiavi, SC; Altinişik, G; Jakopović, M; Inoue, Y; McCormack, FX (2015). "Modeling pulmonary alveolar microlithiasis by epithelial deletion of the Npt2b sodium phosphate cotransporter reveals putative biomarkers and strategies for treatment". Sci Transl Med. 7 (313): 313ra181. doi:10.1126/scitranslmed.aac8577. PMC   4764987 . PMID   26560359.
  17. ↑ Barnard, NJ; Crocker, PR; Blainey, AD; Davies, RJ; Ell, SR; Levison, DA (1987). "Pulmonary alveolar microlithiasis. A new analytical approach". Histopathology. 11 (6): 639–645. doi:10.1111/j.1365-2559.1987.tb02674.x. PMID   3623431. S2CID   9063464.
  18. 1 2 Marchiori, E; Gonçalves, CM; Escuissato, DL; Teixeira, KI; Rodrigues, R; Barreto, MM; Esteves, M (2007). "Pulmonary alveolar microlithiasis: high-resolution computed tomography findings in 10 patients". J Bras Pneumol. 33 (5): 552–557. doi: 10.1590/S1806-37132007000500010 . PMID   18026653.
  19. ↑ Sahin, U; Yildiz, M; Bircan, HA; Akkaya, A; Candir, O (2004). "Absence of pulmonary uptake of Tc-99m methylenediphosphonate in alveolar microlithiasis". Ann Nucl Med. 18 (8): 695–698. doi:10.1007/bf02985964. PMID   15682851. S2CID   21539088.
  20. ↑ Helbich, TH; Wojnarovsky, C; Wunderbaldinger, P; Heinz-Peer, G; Eichler, I; Herold, CJ (1997). "Pulmonary alveolar microlithiasis in children: radiographic and high- resolution CT findings". AJR Am J Roentgenol. 168 (1): 63–65. doi:10.2214/ajr.168.1.8976922. PMID   8976922.
  21. ↑ Cluzel, P; Grenier, P; Bernadac, P; Laurent, F; Picard, JD (1991). "Pulmonary alveolar microlithiasis: CT findings". J Comput Assist Tomogr. 15 (6): 938–942. doi:10.1097/00004728-199111000-00006. PMID   1939772.
  22. 1 2 Schmidt, H; Lörcher, U; Kitz, R; Zielen, S; Ahrens, P; König, R (1996). "Pulmonary alveolar microlithiasis in children". Pediatr Radiol. 26 (1): 33–36. doi:10.1007/bf01403701. PMID   8598991. S2CID   21628116.
  23. 1 2 Deniz, O; Ors, F; Tozkoparan, E; Ozcan, A; Gumus, S; Bozlar, U; Bilgic, H; Ekiz, K; Demirci, N (2005). "High resolution computed tomographic features of pulmonary alveolar microlithiasis". Eur J Radiol. 55 (3): 452–460. doi:10.1016/j.ejrad.2005.01.010. PMID   16129256.
  24. ↑ Hoshino, H; Koba, H; Inomata, S; Kurokawa, K; Morita, Y; Yoshida, K; Akiba, H; Abe, S (1998). "Pulmonary alveolar microlithiasis: highresolution CT and MR findings". J Comput Assist Tomogr. 22 (2): 245–248. doi:10.1097/00004728-199803000-00016. PMID   9530388.
  25. ↑ Gasparetto, EL; Tazoniero, P; Escuissato, DL; Marchiori, E; Frare, E; Silva, RL; Sakamoto, D (2004). "Pulmonary alveolar microlithiasis presenting with crazy-paving pattern on high resolution CT". Br J Radiol. 77 (923): 974–976. doi:10.1259/bjr/96331922. PMID   15507428.
  26. ↑ Stamatis, G; Zerkowski, HR; Doetsch, N; Greschuchna, D; Konietzko, N; Reidemeister, JC (1993). "Sequential bilateral lung transplantation for pulmonary alveolar microlithiasis". Ann Thorac Surg. 56 (4): 972–975. doi:10.1016/0003-4975(93)90370-w. PMID   8215680.
  27. ↑ Alkhankan, Emad; Yamin, Hasan; Bukamur, Hazim; Alkhankan, Fadi; Shweihat, Yousef; Zeid, Fuad (June 2019). "Pulmonary alveolar microlithiasis diagnosed with radiography, CT, and bone scintigraphy". Radiology Case Reports. 14 (6): 775–777. doi:10.1016/j.radcr.2019.03.032. ISSN   1930-0433. PMC   6460250 . PMID   31011377.
  28. ↑ Alrossais, Naif M.; Alshammari, Abdullah M.; Alrayes, Abdullah M.; Mohammad, Najwa; Al-Amoodi, Mohamed J. H.; Almutairi, Ashwaq M.; Alsuhaymi, Abdulsalam O.; Alhadid, Daeya A.; Alhammad, Fatima A.; Ouf, Nida H.; Ahmed, Mohammed H.; Saleh, Waleed; AlAmodi, Abdulhadi A. (2019-07-28). "Pulmonary Hypertension and Polycythemia Secondary to Pulmonary Alveolar Microlithiasis Treated with Sequential Bilateral Lung Transplant: A Case Study and Literature Review". The American Journal of Case Reports. 20: 1114–1119. doi:10.12659/AJCR.911045. ISSN   1941-5923. PMC   6683309 . PMID   31352464.
  29. ↑ Ozcelik, U; Yalcin, E; Ariyurek, M; Ersoz, DD; Cinel, G; Gulhan, B; Kiper, N (2010). "Long-term results of disodium etidronate treatment in pulmonary alveolar microlithiasis". Pediatr Pulmonol. 45 (5): 514–517. doi:10.1002/ppul.21209. PMID   20425862. S2CID   44706545.
  30. ↑ Ferreira Francisco, Flávia Angélica; Pereira e Silva, Jorge Luiz; Hochhegger, Bruno; Zanetti, Gláucia; Marchiori, Edson (January 2013). "Pulmonary alveolar microlithiasis. State-of-the-art review". Respiratory Medicine. 107 (1): 1–9. doi: 10.1016/j.rmed.2012.10.014 . ISSN   1532-3064. PMID   23183116.
  31. ↑ Mariotta, S; Guidi, L; Mattia, P; Torrelli, L; Pallone, G; Pedicelli, G; Bisetti, A (1997). "Pulmonary microlithiasis. Report of two cases". Respiration. 64 (2): 165–169. doi:10.1159/000196663. PMID   9097354.
  32. ↑ Castellana, G; Gentile, M; Castellana, R; Fiorente, P; Lamorgese, V (2002). "Pulmonary alveolar microlithiasis: clinical features, evolution of the phenotype, and review of the literature". Am J Med Genet. 111 (2): 220–224. doi:10.1002/ajmg.10530. PMID   12210357.
  33. ↑ "Rare Lung Diseases > Learn More > Disorder Definitions".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.